Sanofi Net Profit Margin 2010-2023 | SNY

Current and historical net profit margin for Sanofi (SNY) from 2010 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue. Sanofi net profit margin for the three months ending December 31, 2023 was .
Sanofi Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2023-12-31 $50.27B $5.84B 11.63%
2023-09-30 $49.01B $9.68B 19.75%
2023-06-30 $48.42B $9.02B 18.63%
2023-03-31 $48.20B $8.71B 18.06%
2022-12-31 $47.82B $8.82B 18.44%
2022-09-30 $48.72B $8.33B 17.09%
2022-03-31 $34.76B $6.88B 19.78%
2021-09-30 $35.03B $6.90B 19.70%
2021-03-31 $43.57B $7.99B 18.34%
2020-09-30 $42.75B $7.39B 17.29%
2020-03-31 $41.19B $6.36B 15.44%
2019-09-30 $41.49B $4.98B 12.00%
2019-03-31 $41.50B $4.86B 11.70%
2018-03-31 $41.43B $4.71B 11.36%
2017-12-31 $40.92B $9.53B 23.30%
2017-09-30 $40.25B $9.90B 24.58%
2017-06-30 $39.59B $9.92B 25.06%
2017-03-31 $39.14B $10.09B 25.77%
2016-12-31 $38.41B $5.21B 13.57%
2016-09-30 $39.27B $6.19B 15.75%
2016-06-30 $39.37B $5.76B 14.63%
2016-03-31 $41.16B $5.52B 13.40%
2015-09-30 $42.97B $4.90B 11.40%
2015-06-30 $43.92B $4.59B 10.45%
2014-06-30 $44.70B $5.57B 12.45%
2013-06-30 $45.22B $6.39B 14.12%
2012-06-30 $46.75B $8.61B 18.41%
2012-03-31 $47.10B $8.56B 18.17%
2011-12-31 $47.27B $9.33B 19.74%
2011-09-30 $45.65B $8.04B 17.61%
2011-06-30 $44.35B $7.45B 16.81%
2011-03-31 $42.93B $8.22B 19.15%
2010-12-31 $41.26B $8.24B 19.96%
2010-09-30 $41.28B $9.30B 22.53%
2010-06-30 $41.42B $10.37B 25.04%
2010-03-31 $41.35B $11.38B 27.52%
2009-12-31 $40.79B $10.99B 26.95%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $123.116B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.86
Pfizer (PFE) United States $162.291B 20.17
Innoviva (INVA) United States $0.998B 7.01